🔍

NGLFINE - NGL Fine Chem

📊 NSE: NGLFINE 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/14/2025 10:31

📢 Recent Corporate Announcements

NGL Fine-Chem Credit Rating Outlook Upgraded to 'Stable' from 'Negative'

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 13 Mar 2026, 12:19 PM

CRISIL Ratings has revised the outlook on NGL Fine-Chem Limited's long-term bank loan facilities to 'Stable' from 'Negative'. While the outlook has improved, the long-term rating itself has been reaffirmed at 'CRISIL BBB+'. Additionally, the company's short-term rating was reaffirmed at 'CRISIL A2'. This revision indicates a stabilization in the company's credit profile and a reduced risk of a rating downgrade in the near term.

Outlook on long-term bank facilities revised to 'Stable' from 'Negative'
Long-term credit rating reaffirmed at 'CRISIL BBB+'
Short-term credit rating reaffirmed at 'CRISIL A2'
Rating action communicated by CRISIL Ratings on March 12, 2026

💡 Investors should view the outlook upgrade as a sign of improving financial stability; however, continue to monitor quarterly earnings for sustained operational growth.

NGL Fine-Chem Q3FY26 PAT Jumps 1129% YoY to ₹15.69 Cr; EBITDA Margin Hits 17.5%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Feb 2026, 05:27 PM

NGL Fine-Chem reported a robust Q3FY26 with revenue growing 43.11% YoY to ₹127.51 crore, driven by higher volumes and stable realizations. Profitability saw a massive jump, with PAT rising over 11-fold to ₹15.69 crore and EBITDA margins expanding to 17.50% from 5.72% a year ago. The company's major greenfield expansion at Tarapur is on track with a revised investment of ₹210 crore, targeting commissioning in Q1FY27. Management expects commercial production from this facility to start in H2FY27, aiming for an asset turnover of over two times.

Revenue from operations grew 43.11% YoY to ₹127.51 crore in Q3FY26.
EBITDA margin improved significantly to 17.50% compared to 5.72% in the previous year's quarter.
Animal API remains the core segment, contributing 92% of the total revenue mix.
Greenfield expansion project cost revised to ₹210 crore with ₹156 crore already invested; commissioning expected in Q1FY27.
Debt for the expansion project is capped at ₹85 crore, with the remainder funded via internal accruals.

💡 Investors should note the significant margin recovery and the upcoming capacity expansion which could drive the next leg of growth. Monitor the commissioning of the Tarapur facility in Q1FY27 and the subsequent ramp-up in H2FY27.

NGL Fine-Chem Q3 PAT Surges to ₹15.69 Cr; Revenue Up 43% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 08:25 PM

NGL Fine-Chem reported a stellar performance for Q3 FY26, with consolidated net profit jumping to ₹15.69 crore from just ₹1.28 crore in the same quarter last year. Revenue from operations grew by 43.1% YoY to ₹127.51 crore, reflecting strong operational recovery. For the nine-month period ending December 2025, the company has already surpassed its full-year FY25 profit, reaching ₹34.56 crore. Additionally, the company appointed Shivam Gharat as the new Company Secretary and Compliance Officer.

Consolidated Net Profit rose exponentially to ₹15.69 crore in Q3 FY26 from ₹1.28 crore in Q3 FY25.
Revenue from operations increased 43.1% YoY to ₹127.51 crore compared to ₹89.10 crore in the previous year.
Basic EPS saw a massive jump to ₹25.40 in Q3 FY26 from ₹2.07 in the year-ago period.
Nine-month consolidated PAT stands at ₹34.56 crore, significantly higher than the ₹20.31 crore reported in the same period last year.
Shivam Gharat appointed as Company Secretary and Compliance Officer effective February 3, 2026.

💡 The company is showing strong growth momentum with nine-month profits already exceeding the previous full year's performance. Investors should maintain a positive outlook while monitoring the impact of new labour code regulations on future employee benefit costs.

NGL Fine-Chem Q3 PAT Surges 1129% YoY to ₹15.69 Cr; Revenue Up 43%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 08:09 PM

NGL Fine-Chem reported a stellar performance for the quarter ended December 31, 2025, with consolidated revenue growing 43% YoY to ₹127.51 crore. The net profit saw an exponential jump of 1129% YoY, reaching ₹15.69 crore compared to ₹1.28 crore in the same quarter last year. On a sequential basis, profits grew by 63%, driven by significantly improved operating margins and higher other income. The company also announced the appointment of Shivam Gharat as the new Company Secretary and Compliance Officer.

Consolidated Revenue from Operations increased 43.1% YoY to ₹12,750.99 lakhs.
Net Profit (PAT) skyrocketed to ₹1,569.07 lakhs from ₹127.66 lakhs in the previous year's corresponding quarter.
Earnings Per Share (EPS) improved significantly to ₹25.40 from ₹2.07 YoY.
Profit Before Tax (PBT) margins expanded to 16.2% in Q3 FY26 compared to 1.4% in Q3 FY25.
Nine-month (9M) PAT stands at ₹34.56 crore, already surpassing the full FY25 PAT of ₹21.12 crore.

💡 The stock is expected to react very positively to this massive turnaround in profitability and margin expansion. Investors should hold the stock while monitoring the sustainability of these high margins in future quarters.

NGL Fine-Chem Q3 PAT Surges 1129% YoY to ₹15.69 Cr; Revenue Up 43%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 08:07 PM

NGL Fine-Chem reported a stellar performance for Q3 FY26, with consolidated revenue growing 43% YoY to ₹127.51 crore. The net profit witnessed a massive jump of 1129% YoY, reaching ₹15.69 crore compared to ₹1.28 crore in the same quarter last year. On a sequential basis, profits rose by 63%, indicating strong operational momentum. The company also announced the appointment of Shivam Gharat as the new Company Secretary and Compliance Officer.

Consolidated Revenue from Operations rose 43.1% YoY to ₹12,750.99 lakhs.
Net Profit (PAT) skyrocketed to ₹1,569.07 lakhs from ₹127.66 lakhs in the previous year's corresponding quarter.
Profit Before Tax (PBT) for the quarter stood at ₹2,066.99 lakhs, a significant jump from ₹126.53 lakhs YoY.
Nine-month (9M FY26) PAT reached ₹3,455.67 lakhs, already exceeding the full FY25 PAT of ₹2,112.43 lakhs.
Basic EPS for the quarter increased to ₹25.40 from ₹2.07 in Q3 FY25.

💡 The stock is expected to react very positively to this massive turnaround in profitability and robust revenue growth. Investors should hold the stock while monitoring the sustainability of these high margins in future quarters.

NGL Fine-Chem Company Secretary & Compliance Officer Pallavi Pednekar Resigns

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 05 Jan 2026, 02:39 PM

NGL Fine-Chem Limited has announced the resignation of Mrs. Pallavi Pednekar from her role as Company Secretary and Compliance Officer, effective January 23, 2026. She is stepping down to pursue career opportunities outside the organization after serving as a Key Managerial Personnel (KMP). The company has confirmed there are no other material reasons for her departure. NGL Fine-Chem is currently in the process of identifying a suitable successor to ensure regulatory compliance.

Mrs. Pallavi Pednekar to step down as Company Secretary and Compliance Officer effective January 23, 2026.
The resignation was officially tendered on January 5, 2026, providing an 18-day transition period.
The departure is categorized as a resignation to pursue outside career interests with no material concerns cited.
The company is actively seeking a replacement to fill the vacancy in the KMP role.

💡 This is a routine administrative change and should not impact the company's core operations. Investors should monitor for the appointment of a new Compliance Officer to ensure continued regulatory adherence.

NGL Fine-Chem Submits Q3 FY26 Share Dematerialization Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Jan 2026, 12:59 PM

NGL Fine-Chem Limited has filed its quarterly compliance report under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that all physical share certificates received for dematerialization between October 1 and December 31, 2025, were processed and cancelled within 15 days. Approximately 3,000 shares were transitioned from physical to electronic form during this period. This is a standard administrative procedure to ensure the accuracy of the company's shareholding records.

Quarterly compliance for the period October 1, 2025, to December 31, 2025
Total of 3,000 shares dematerialized across multiple folios during the quarter
Processing of demat requests completed within the mandatory 15-day window
Verification and cancellation confirmed by Registrar Purva Sharegistry (I) Pvt. Ltd.

💡 This is a routine regulatory update with no impact on the company's business fundamentals. Investors do not need to take any specific action.

NGL Fine-Chem to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Dec 2025, 10:44 AM

NGL Fine-Chem Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the official declaration of the audited financial results. This is a standard regulatory procedure for listed companies to prevent insider trading before earnings announcements.

Trading window closure effective from January 1, 2026
Closure is related to the financial results for the quarter ending December 31, 2025
Window to reopen 48 hours after the results are declared to the exchanges
Restriction applies to all officers, designated employees, directors, and auditors

💡 No action is required as this is a routine regulatory filing. Investors should look forward to the upcoming quarterly earnings report for fundamental performance updates.

NGL Fine-Chem Limited Concludes Meeting with Ten Individual and Institutional Investors

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Dec 2025, 04:59 PM

NGL Fine-Chem Limited conducted a meeting with a group of 10 investors on December 23, 2025. The participants included individuals such as Yogansh Jeswani, Ayush Agarwal, and Rahul Agrawal. The company confirmed that the discussions were strictly based on publicly available information to ensure compliance with SEBI regulations. No unpublished price sensitive information (UPSI) was shared during the interaction. This filing serves as a routine update following the company's prior intimation on December 18, 2025.

Meeting held on December 23, 2025, with 10 specific investors and analysts.
Disclosure made under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Company explicitly stated that no Unpublished Price Sensitive Information (UPSI) was discussed.
Follow-up to the initial meeting intimation provided to exchanges on December 18, 2025.

💡 This is a routine regulatory disclosure with no immediate impact on stock fundamentals. Investors should continue to track quarterly earnings for material updates on company performance.

NGL Fine-Chem Reschedules One-on-One Investor Meeting to December 24, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Dec 2025, 03:21 PM

NGL Fine-Chem Limited has informed the exchanges that its scheduled one-on-one investor meeting has been rescheduled. The meeting, which was previously intimated on December 18, 2025, will now take place on Wednesday, December 24, 2025. The interaction will be held in a virtual mode. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the discussion.

One-on-one investor meeting rescheduled to December 24, 2025
The meeting will be conducted via virtual mode
Follows a previous intimation made by the company on December 18, 2025
Company confirms no unpublished price sensitive information will be discussed

💡 This is a routine administrative update regarding investor relations; no immediate action is required from shareholders. Investors should look for any subsequent disclosures if the meeting results in a public transcript.

NGL Fine-Chem Schedules Investor and Analyst Virtual Meeting for December 23, 2025

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Dec 2025, 12:24 PM

NGL Fine-Chem Limited has announced a virtual meeting between Managing Director Rahul Nachane and institutional investors/analysts scheduled for December 23, 2025. The company has already made its latest investor presentation available on its website and stock exchange platforms for public review. This meeting is a standard part of the company's investor relations program to discuss business performance based on public data. Management has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session.

Virtual meeting scheduled for December 23, 2025, with Managing Director Rahul Nachane.
Investor presentation has been pre-filed with BSE and NSE for public access.
The meeting aims to facilitate interaction with institutional participants and analysts.
Company confirms strict adherence to SEBI regulations regarding non-disclosure of UPSI.

💡 Investors should review the existing investor presentation on the company website to stay updated on the firm's strategic direction. No immediate action is required as this is a routine transparency-focused event.

View All NGLFINE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, Animal API contributed 90% of revenue (down from 94% in Q2 FY25), Human API 4% (up from 3%), Intermediates 5% (up from 2%), and Formulations 1% (down from 2%). Overall revenue grew 28.64% YoY to INR 120.26 Cr in Q2 FY26.

Geographic Revenue Split

NGL derives approximately 25% of its sales from the domestic market and the remaining 75% from export sales to semi-regulated markets in Europe, Asia Pacific, West Asia, and Latin America.

Profitability Margins

Operating margins moderated to 10.2% in FY25 from approximately 17% in FY24 due to intense competition and rising costs. However, Q2 FY26 saw a recovery with EBITDA margins expanding to 14.27% from 10.54% YoY.

EBITDA Margin

EBITDA margin stood at 14.27% in Q2 FY26, representing a 373 bps improvement YoY. Core profitability is recovering from a low of 10.2% in FY25 as demand stabilizes and volume increases.

Capital Expenditure

The company is undertaking a Greenfield expansion at Tarapur with a total estimated capex of INR 160 Cr. As of Q2 FY26, INR 133.29 Cr has been invested, with commercial production expected in the latter half of FY27.

Credit Rating & Borrowing

CRISIL has a 'Negative' outlook due to subdued margins, while ICRA maintains a 'Stable' outlook. Interest coverage remained healthy at 11.55 times in FY25 despite margin pressure.

⚙️ Operational Drivers

Raw Materials

Major raw materials include N-2 and N-3 level intermediates and solvents used in API manufacturing. These are susceptible to price volatility which impacts margins due to short-term contracts.

Capacity Expansion

Greenfield expansion at Tarapur is underway (INR 160 Cr) to serve regulated markets. Brownfield expansion at subsidiary Macrotech for intermediates is completed and commercial production has started.

Raw Material Costs

Raw material costs are a significant portion of the cost base; realizations were impacted in FY25 by competition, while revenue remained stable due to increased volumes. Procurement is managed via short-term contracts.

Manufacturing Efficiency

75% of production currently comes from Zero Liquid Discharge (ZLD) facilities, reflecting high environmental compliance and operational standards.

📈 Strategic Growth

Growth Strategy

Growth will be driven by entering regulated markets (US and Europe) which offer higher margins, launching new products from the pipeline, and the commissioning of the Tarapur Greenfield plant in H2 FY27.

Products & Services

Key products include veterinary APIs such as Nitroxynil, Clorsulon, and Buparvaquone, which account for 85-90% of total sales.

Brand Portfolio

NGL Fine-Chem Limited.

New Products/Services

Validation batches for regulated markets are currently being manufactured in the new Tarapur clean rooms to generate data for regulatory submissions.

Market Expansion

Targeting regulated markets in the US and Europe to diversify from current semi-regulated market dominance.

🌍 External Factors

Industry Trends

The industry is seeing a recovery in demand for animal health APIs. There is a clear trend toward capacity expansion and shifting focus to regulated markets to capture higher margins and offset competitive pricing in semi-regulated regions.

Competitive Landscape

Mid-sized player facing intense competition from both domestic Indian manufacturers and international players, particularly in the unregulated market segments.

Competitive Moat

Moat is built on decades of experience in API manufacturing, a strong global client base of over 400 customers, and partial backward integration for basic chemicals which supports a competitive cost proposition.

Geopolitical Risks

Exposure to international markets in Europe, Latin America, and Asia Pacific makes the company sensitive to global trade barriers and regulatory changes.

⚖️ Regulatory & Governance

Industry Regulations

Regulatory audits for the new Tarapur facility are anticipated to commence in Q2 FY27. Successful audits are a prerequisite for commercial production for regulated markets.

Environmental Compliance

75% of production is from Zero Liquid Discharge facilities. The company invested INR 133.29 Cr in the Tarapur project which includes high-standard clean rooms for regulatory compliance.

Legal Contingencies

The auditor's report for FY25 expressed an unmodified opinion on internal financial controls; no specific pending litigation values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the successful outcome of regulatory audits for the Tarapur plant, which is critical for the H2 FY27 production timeline and margin expansion strategy.